J Gynecol Oncol.  2008 Dec;19(4):236-240. 10.3802/jgo.2008.19.4.236.

Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases

• Kim JH
• Lee SJ
• Bae JH
• Lee SH
• Bae SN
• Namkoong S
• Park JS

• KMID: 2173412
• DOI: http://doi.org/10.3802/jgo.2008.19.4.236

Abstract

OBJECTIVE
We assessed the prognostic factors and the efficacy of adjuvant therapy and reviewed randomized studies carried out on patients receiving adjuvant therapy with early endometrial carcinoma.
METHODS
One hundred and five patients that received primary surgical treatment for stage IB, IC and II endometrial cancer were enrolled in this study. The clinical outcomes were compared among the patients with variable prognostic factors and adjuvant treatments.
RESULTS
One hundred and five patients fulfilled the eligibility criteria and 46 patients (43.8%) underwent adjuvant therapy. Disease recurrence occurred in nine patients within a median time of 24 months. Cervical involvement was an independent prognostic factor for the disease-free survival rates. Eight of 16 patients with FIGO stage II disease received adjuvant chemotherapy consisting of cisplatin and etoposide (or cyclophosphamide) or combined chemoradiation. The 5-year disease-free survival rate for these patients was 87.5%, a value significantly higher than for patients that received radiation therapy alone (30%).
CONCLUSION
Adjuvant chemotherapy or combination chemo-radiotherapy might be superior to radiation therapy alone in high-risk early endometrial cancer patients.

Keyword

Endometrial carcinoma; Adjuvant therapy; Prognostic factor

MeSH Terms

Chemotherapy, Adjuvant
Cisplatin
Disease-Free Survival
Endometrial Neoplasms
Etoposide
Female
Humans
Recurrence
Retrospective Studies
Cisplatin
Etoposide

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin. 2005. 55:74–108.

2. SOG Gynecologic Oncology Committee. Annual report of gynecologic cancer registry program in Korea for 2004 (Jan. 1st, 2004-Dec. 31st, 2004). Korean J Obstet Gynecol. 2007. 50:28–78.

3. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial.PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000. 355:1404–1411.

4. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol. 1991. 40:55–65.

5. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980. 56:419–427.

6. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2004. 92:744–751.

7. FIGO stages: 1988 revision. Gynecol Oncol. 1989. 35:125–127.

8. Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001. 11:430–437.

9. Descamps P, Calais G, Moire C, Bertrand P, Castiel M, Le Floch O, et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol. 1997. 64:54–58.

10. Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR. Results of radiotherapy in recurrent endometrial carcinoma: A retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys. 1989. 17:29–34.

11. Vavra N, Denison U, Kucera H, Barrada M, Kurz C, Salzer H, et al. Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gynecol Scand. 1993. 72:205–209.

12. Lybeert ML, van Putten WL, Brolmann HA, Coebergh JW. Postoperative radiotherapy for endometrial carcinoma. Stage I. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in the southeast Netherlands. Eur J Cancer. 1998. 34:586–590.

13. Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997. 24:1 Suppl 1. S1–S140. S141–S150.

14. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985. 151:1009–1015.

15. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM, et al. Clinical stage I endometrial cancer: Prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys. 1992. 22:905–911.

16. Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: Predictors of distant failure and death. Gynecol Oncol. 2002. 87:274–280.

17. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis. BJOG. 2007. 114:1313–1320.

18. Lukka H, Whelan T, Blake P, Swart AM, Orton J, Branson A, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer: Results of the randomized MRC ASTEC and NCIC CTG EN.5 Trials, a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2008. 72:1 Suppl 1. S353–S354.

19. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC, 2 trial [abstract]. J Clin Oncol. 2008. 26(15S):Abstract LBA5503.

20. Randall ME, Spirtos NM, Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr. 1995. (19):13–15.

21. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane collaboration. Ann Oncol. 2007. 18:409–420.

22. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2004. 22:2159–2166.

23. Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008. 18:803–808.

24. Hirai M, Hirono M, Oosaki T, Hayashi Y, Yoshihara T, Itami M. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynaecol Obstet. 2002. 78:37–44.

25. Aoki Y, Watanabe M, Amikura T, Obata H, Sekine M, Yahata T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol. 2004. 94:333–339.

26. Kodama J, Seki N, Hiramatsu Y. Chemotherapy for high-risk early-stage endometrial cancer. Curr Opin Obstet Gynecol. 2007. 19:42–47.

27. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer. 2006. 95:266–271.

28. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008. 108:226–233.

29. Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT){+/-} chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol. 2007. 25(18S):Abstract 5503.

30. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006. 103:155–159.